Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: Molecular and Clinical Markers for the Diagnosis and Management of Type 1 VWD (MCMDM-1VWD)
Open Access
- 15 May 2008
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 111 (10), 4979-4985
- https://doi.org/10.1182/blood-2007-09-110940
Abstract
The decreased survival of von Willebrand factor (VWF) in plasma has been implicated as a mechanism in a subset of type 1 von Willebrand disease (VWD) patients. We have previously reported that the ratio of plasma levels of VWF and its propeptide (VWFpp) can be used to identify patients with reduced VWF survival. In this study, we report the assay of VWFpp and VWF:Ag in 19 individuals recruited from 6 European centers within the MCMDM-1VWD study. Eight individuals had a VWF:Ag level less than 30 IU/dL. Seven of these patients had a robust desmopressin response and significantly reduced VWF half-life that was predicted by a markedly increased steady-state plasma VWFpp/VWF:Ag ratio. VWF mutations previously associated with reduced VWF survival were identified in each of the 7 individuals. Thus, a substantially increased ratio of steady-state VWFpp/VWF:Ag predicted a reduced VWF half-life in patients with markedly decreased VWF:Ag levels. These data indicate that a reduced VWF survival is found in a subpopulation of patients with type 1 VWD. The systematic assay of both plasma VWF and the VWF propeptide in moderately severe type 1 VWD patients may identify patients with a reduced VWF survival phenotype.Keywords
This publication has 45 references indexed in Scilit:
- Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWDBlood, 2008
- The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort studyBlood, 2007
- Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survivalBlood, 2006
- The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort studyBlood, 2006
- Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWDJournal of Thrombosis and Haemostasis, 2006
- An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand diseaseThrombosis and Haemostasis, 2006
- Genetic analysis of 31 Swedish type 1 von Willebrand disease families reveals incomplete linkage to the von Willebrand factor gene and a high frequency of a certain disease haplotypeJournal of Thrombosis and Haemostasis, 2005
- Cysteine-mutations in von Willebrand factor associated with increased clearanceJournal of Thrombosis and Haemostasis, 2005
- Increased clearance of von Willebrand factor antigen post-DDAVP in Type 1 von Willebrand disease: is it a potential pathogenic process?Journal of Thrombosis and Haemostasis, 2003
- von Willebrand's disease antigen II. A new plasma and platelet antigen deficient in severe von Willebrand's disease.JCI Insight, 1978